Sugi Predict

Sugi Predict / Compounds / SCHEMBL4085333

SCHEMBL4085333

SCHEMBL4085333

CCCCNS(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 7/20 0.80
▸ CA1 P00915 7/20 0.80
▸ CA2 P00918 7/20 0.80
▸ CA9 Q16790 7/20 0.80
▸ CYP3A4 P08684 1/20 0.66
▸ CYP2D6 P10635 1/20 0.60
▸ LMNA P02545 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ PRMT1 Q99873 1/20 0.57
▸ CA6 P23280 1/20 0.55
▸ CA5A P35218 1/20 0.55
▸ CA7 P43166 1/20 0.55
▸ CA14 Q9ULX7 1/20 0.55
▸ CA5B Q9Y2D0 1/20 0.55
▸ ALDH1A1 P00352 4/20 0.54
▸ TSHR P16473 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ ALOX12 P18054 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1082403 0.95 CA12 (0.77) CA12CA1CA2CA9CYP3A4
SCHEMBL27661888 0.93 CA12 (0.75) CA12CA1CA2CA9CYP3A4
SCHEMBL27681903 0.93 CA12 (0.75) CA12CA1CA2CA9CYP3A4
SCHEMBL8761233 0.93 CA12 (0.75) CA12CA1CA2CA9CYP3A4
SCHEMBL27843904 0.93 CA12 (0.75) CA12CA1CA2CA9CYP3A4
SCHEMBL11246926 0.91 CA12 (0.67) CA12CA1CA2CA9CYP3A4
SCHEMBL4773010 0.89 CA1 (1.00) CA12CA1CA2CA9CYP3A4
SCHEMBL9796343 0.86 SMN1; SMN2 (0.59) CA12CA1CA2CA9LMNA
SCHEMBL17795416 0.84 LMNA (0.60) CA12CA1CA2CA9LMNA
SCHEMBL187922 0.84 ALDH1A1 (0.72) CA12CA2CA9LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117900019-A Low-alkali beneficiation separation method for high-sulfur low-zinc refractory sulfide ore 长沙矿山研究院有限责任公司 2024-04-19 — — CN claimed
EP-4719413-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF Animol Discovery, Inc. (US) 2026-04-08 — — EP disclosed
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY INC (US) 2026-04-02 — — US disclosed
WO-2024246837-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY, INC. (US) 2024-12-05 — — WO disclosed
CN-117900019-A Low-alkali beneficiation separation method for high-sulfur low-zinc refractory sulfide ore 长沙矿山研究院有限责任公司 2024-04-19 — — CN disclosed
US-20210060995-A1 THERMAL TRANSFER RECORDING SHEET CANON KABUSHIKI KAISHA (JP) 2021-03-04 — — US disclosed
US-9994728-B2 Photosensitive resin composition and color filter using the same SAMSUNG SDI CO., LTD. (KR) 2018-06-12 — — US disclosed
US-9994728-B2 Photosensitive resin composition and color filter using the same SAMSUNG SDI CO., LTD. (KR) 2018-06-12 — — US disclosed
CN-106146358-B Method for synthesizing amino- (N-alkyl) benzene sulfonamide 南京理工大学 2018-01-23 — — CN disclosed
CN-106146358-A Method for synthesizing amino- (N-alkyl) benzene sulfonamide 南京理工大学 2016-11-23 — — CN disclosed
EP-1873200-A1 An improved process for making an external plasticization of aliphatic polyamides and plasticizers useful for said plasticization Arkema France (FR) 2008-01-02 — — EP disclosed
CN-1995150-A Slightly water-soluble sulfonamide type dye for dying hydrophobic fiber and its preparation UNIV DALIAN TECH (CN) 2007-07-11 — — CN disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
EP-0644453-A1 Organic nonlinear optical materials HOECHST AKTIENGESELLSCHAFT (DE) 1995-03-22 — — EP disclosed
CN-1030080-A The preparation method of herbicides of sulfonylurea, the composition that contains and its utilization RHONE POULENC AGROCHIMIE (FR) 1989-01-04 — — CN disclosed
US-4137228-A HIGH TINCTORIAL STRENGTH, COLORFASTNESS CASSELLA AKTIENGESELLSCHAFT (DE) 1979-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CA12 4759/4885CA1 4464/4885CA2 3233/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CA12 4759/4885CA1 4464/4885CA2 3233/4885
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF JAK1, JAK3, JAK2 CA12 4095/4885CA1 2926/4885CA2 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.